Your unwavering support has enabled us to emerge as the biggest winner at Refinitiv Lipper Fund Awards 2023! We will continue to focus on delivering superior returns over the long term to you, our unitholders. Thank you for making this success possible.

Investors are advised to read and understand the contents of the Master Prospectus 1 of Public Series of Funds, Master Prospectus 1 of Public Series of Shariah-based Funds, and Master Prospectus 1 of PB Series of Funds dated 30 April 2019; Master Prospectus of Public e-Series of Funds and Master Prospectus of Public e-Series of Shariah-based Funds dated 1 July 2020; 1^st Supplemental Prospectus of Master Prospectus 1 of Public Series of Funds and 1^st Supplemental Prospectus of Master Prospectus 1 of Public Series of Shariah-based Funds dated 22 January 2020, 2^nd Supplemental Prospectus of Master Prospectus 1 of Public Series of Funds, 2^nd Supplemental Prospectus of Master Prospectus 1 of Public Series of Shariah-based Funds, 1^st Supplemental Prospectus of Master Prospectus 1 of PB Series of Funds, 1^st Supplemental Prospectus of Master Prospectus of Public e-Series of Funds dated 16 December 2021; Prospectus of PB Global Technology & Healthcare Fund dated 9 May 2019 and the relevant fund’s Product Highlights Sheet (PHS) before investing.

Investors should understand, compare and consider the risks, fees, charges and costs involved in investing in a fund. A copy of the Prospectus, Supplemental Prospectus and PHS can be viewed at our website.

Investors should make their own assessment of the merits and risks of the investment. If in doubt, investors should seek professional advice. Please refer to our website for our investment disclaimer.